OAM
KRYS icon

Oppenheimer Asset Management’s Krystal Biotech KRYS Stock Holding History

Oppenheimer Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$205K Sell
793
-251
-24% -$66.8K ﹤0.01% 1060
2025
Q4 		$257K Sell
1,044
-219
-17% -$46.1K ﹤0.01% 947
2025
Q3 		$223K Buy
+1,263
New +$189K ﹤0.01% 1070
2025
Q2 		– Sell
-1,269
Closed -$229K – 1186
2025
Q1 		$229K Buy
+1,269
New +$213K ﹤0.01% 1022
2024
Q4 		– Sell
-1,289
Closed -$235K – 1178
2024
Q3 		$235K Buy
+1,289
New +$249K ﹤0.01% 1056

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oppenheimer Asset Management's KRYS Position: Q1 2026 in Review

Oppenheimer Asset Management reduced its Krystal Biotech (KRYS) stake by 24% in Q1 2026, selling an estimated $66.8K and leaving 793 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #1060.

Oppenheimer Asset Management first reported a position in KRYS in Q3 2024 and has held it in 5 quarters since. The position peaked at $257K in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Oppenheimer Asset Management held 793 shares of Krystal Biotech worth $205K as of Q1 2026.
  • Oppenheimer Asset Management sold 251 Krystal Biotech shares in Q1 2026, an estimated $66.8K.
  • Krystal Biotech made up ﹤0.01% of Oppenheimer Asset Management's portfolio in Q1 2026, its #1060 holding.
  • Oppenheimer Asset Management first reported a position in Krystal Biotech in Q3 2024 and has held it in 5 quarters since.
  • Oppenheimer Asset Management's Krystal Biotech position peaked at $257K in Q4 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.